Loading clinical trials...
Loading clinical trials...
Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants
Conditions
Interventions
VRC01
VRC01LS
+1 more
Locations
14
United States
David Geffen School of Medicine at UCLA NICHD CRS
Los Angeles, California, United States
Univ. of Colorado Denver NICHD CRS
Aurora, Colorado, United States
South Florida CDTC Ft Lauderdale NICHD CRS
Fort Lauderdale, Florida, United States
Univ. of Florida Jacksonville NICHD CRS
Jacksonville, Florida, United States
Pediatric Perinatal HIV Clinical Trials Unit CRS
Miami, Florida, United States
Emory University School of Medicine NICHD CRS
Atlanta, Georgia, United States
Start Date
June 30, 2015
Primary Completion Date
June 17, 2020
Completion Date
December 16, 2021
Last Updated
February 8, 2023
NCT06627764
NCT06694805
NCT04142047
NCT05398185
NCT07428330
NCT07225530
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions